Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Upcoming Conferences

PHILADELPHIA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
October 31, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 7 at 8:30 a.m. ET to Discuss Third Quarter 2017 Results

PHILADELPHIA, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
October 12, 2017 16:51 ET | Source: Spark Therapeutics, Inc.

FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease

Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States ...
October 12, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy

PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
October 03, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in October

PHILADELPHIA, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
September 25, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer

PHILADELPHIA, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
September 20, 2017 07:30 ET | Source: Spark Therapeutics, Inc.; Genethon

Spark Therapeutics Enters into Licensing Agreement with Genethon

PHILADELPHIA and EVRY, France, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic...
September 06, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Publication of Study Confirming Novel Test’s Validity, Reliability and Ability to Detect Change in Functional Vision

PHILADELPHIA, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
August 30, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in September

PHILADELPHIA, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
August 11, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Recognized as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal

PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...